Immune cells armed with a mutation first identified in cancer cells gain potency but don’t turn cancerous themselves.
“Natural T-cell function isn’t good enough. We need to explore the extremes of T-cell function,” says Kole Roybal, an immunologist at the University of California, San Francisco, and co-author of the new paper. What better place to start than with the mutations that turn healthy T cells into hardier, cancerous ones?
Read the article in Nature co-authored by UCSF immunologist, Kole Roybal, PhD.